Kamyar Kalantar-Zadeh M.D. to Drug Administration Schedule
This is a "connection" page, showing publications Kamyar Kalantar-Zadeh M.D. has written about Drug Administration Schedule.
Connection Strength
0.054
-
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. Am Heart J. 2019 11; 217:72-83.
Score: 0.040
-
Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatment. Semin Dial. 2004 Sep-Oct; 17(5):336-41.
Score: 0.014